Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

PHASE3CompletedINTERVENTIONAL
Enrollment

822

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

May 13, 2022

Study Completion Date

May 31, 2022

Conditions
COVID-19
Interventions
DRUG

JT001

Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days

DRUG

Paxlovid

Day 1\~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days

Trial Locations (7)

200020

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

200050

Shanghai Tongren Hospital, Shanghai

200093

Shanghai Public Health Clinical Center, Shanghai

200127

Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

201203

ShuGuang Hospital, Shanghai

201399

Shanghai Pudong Hospital, Shanghai

201900

Huashan Hospital affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Vigonvita Life Sciences

INDUSTRY